This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 44.12% and 9.85%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Does Health Catalyst (HCAT) Have the Potential to Rally 30.43% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 30.4% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Industry Outlook Highlights Inspire Medical Systems, Olink Holding and Health Catalyst
by Zacks Equity Research
Inspire Medical Systems, Olink Holding and Health Catalyst have been highlighted in this Industry Outlook article.
3 Medical Info Systems Stocks Countering Industry-wide Headwinds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Olink Holding (OLK) and Health Catalyst (HCAT) are expected to gain even as COVID-19 severity fades.
NextGen (NXGN) Riding on the Success of Cloud-Based Solution
by Zacks Equity Research
NextGen's (NXGN) cloud-based healthcare technology solutions boost the company's prospect. Strong adoption of its services continues to boost revenues.
Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 50% and 1.16%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Olink Holding AB (publ) Sponsored ADR (OLK) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Olink Holding AB (publ) Sponsored ADR (OLK) delivered earnings and revenue surprises of 25% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Medical Info Systems Stocks Braving Industry-wide Headwinds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like 10x Genomics (TXG), NextGen Healthcare (NXGN) and Health Catalyst (HCAT) are expected to gain as COVID-19 severity fades.
Does Health Catalyst (HCAT) Have the Potential to Rally 61% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 61.5% upside potential for Health Catalyst (HCAT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Can Health Catalyst (HCAT) Climb 113% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 113% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 35% and 2.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Definitive Healthcare Corp. (DH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Definitive Healthcare Corp. (DH) delivered earnings and revenue surprises of 20% and 1.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 72.73% and 1.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 25% and 3.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
RadNet (RDNT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
RadNet (RDNT) delivered earnings and revenue surprises of -650% and 1.84%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
iRhythm Technologies (IRTC) delivered earnings and revenue surprises of 24.53% and 5.97%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 21.79% and 6.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 9.52% and 2.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 5.56% and 6.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Cerner (CERN) Q4 Earnings Top Estimates
by Zacks Equity Research
Cerner (CERN) delivered earnings and revenue surprises of 5.68% and 2.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of -166.67% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 18.18% and 1.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Health Catalyst (HCAT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Health Catalyst (HCAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Health Catalyst, DocuSign, American Homes 4 Rent, MidAmerica Apartment Communities and Apartment Income REIT highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Health Catalyst, DocuSign, American Homes 4 Rent, MidAmerica Apartment Communities and Apartment Income REIT highlighted as Zacks Bull and Bear of the Day
Bull Of The Day: Heath Catalyst (HCAT)
by Brian Bolan
This stock had been reporting losses but posted a break-even quarter in the more recent print and that could start a new trend.